Abbott Consent Decree Highlights Industry's Process Validation Woes
This article was originally published in The Silver Sheet
PROCESS VALIDATION DEFICIENCIES were cited prominently in a recent consent decree between FDA and Abbott Laboratories. The enforcement action underscores the persistent difficulty medical device manufacturers have experienced complying with this area of the quality system regulation. Recent data from FDA indicates that nearly one quarter of firms receiving 483s have process validation problems A new guidance developed by the Global Harmonization Task Force is proving popular with manufacturers, especially in helping decide whether a process should be validated or verified WARNING LETTERS: Biologics IVD firms Calypte, Biopool and Biowhittaker cited for QS reg deficiencies; Vanguard Medical reprocessing operations lack adequate validation, FDA says
You may also be interested in...
UK-based charity International Health Partners has launched a fresh appeal to double the value funds being raised to send essential medicines to expectant mothers and children at risk of death in areas of extreme deprivation.
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.